Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 6/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | OXTR | P30559 | 3/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | EDNRA | P25101 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6292703 | 0.92 | EDNRB (0.36) | EDNRBTP53SMN1; SMN2EDNRACACNA1H | |
| SCHEMBL6293075 | 0.92 | EDNRB (0.34) | EDNRBEDNRAPTGS2 | |
| SCHEMBL6289771 | 0.92 | KEAP1 (0.36) | EDNRBTP53EDNRA | |
| SCHEMBL6289609 | 0.91 | EDNRA (0.39) | EDNRBTP53SMN1; SMN2OXTRAVPR1A | |
| SCHEMBL6288900 | 0.87 | ALDH1A1 (0.34) | EDNRBTP53SMN1; SMN2MAPTPTGS2 | |
| SCHEMBL6289235 | 0.86 | KEAP1 (0.32) | EDNRBEDNRACACNA1H | |
| SCHEMBL6292677 | 0.83 | EDNRA (0.39) | EDNRBEDNRAPTGS2 | |
| SCHEMBL6289642 | 0.83 | EDNRA (0.39) | EDNRBTP53SMN1; SMN2EDNRAPTGER2 | |
| SCHEMBL6293048 | 0.83 | EDNRA (0.40) | EDNRBEDNRA | |
| SCHEMBL6288951 | 0.79 | ALDH1A1 (0.35) | EDNRBTP53SMN1; SMN2EDNRAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962923-B2 | Pyrazole compositions | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20030232848-A1 | Pyrazole compositions | PFIZER INC. | 2003-12-18 | — | — | US | disclosed |
| US-6573270-B1 | Endothelin receptor antagonists | PFIZER INC. | 2003-06-03 | — | — | US | disclosed |
| EP-1072597-A1 | Pyrazoles and their use as endothelin antagonists | Pfizer Limited (GB) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232848-A1 | Pyrazole compositions | EDNRB, EDNRA, AGTR1 | EDNRB 1/4885TP53 3356/4885SMN1; SMN2 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.